Biomarkers for Severity, Therapy, and Disparity in Sarcoidosis: Discovery to Delivery

结节病严重程度、治疗和差异的生物标志物：发现到交付

• 批准号: 9762279
• 负责人: Alicia Gerke
• 金额: $ 1万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9762279
• 关键词: Adrenal Cortex Hormones; Affect; African American; Americas; Arrhythmia; Basic Science; Biological Markers; Blindness; Cardiac Sarcoidosis; Caring; Center for Translational Science Activities; Cirrhosis; Cities; Clinic; Clinical; Clinical Management; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Country; Detection; Development; Diagnosis; Disease; Disease Progression; Disease model; Faculty; Fatigue; Fibrosis; Fostering; Functional disorder; Future; Goals; Granulomatous; Heart failure; Heterogeneity; High Prevalence; Impairment; Inflammation; Interdisciplinary Study; Iowa; Lead; Lung; Mental Depression; Mentorship; Methods; Minority; Modernization; Morbidity - disease rate; Neurologic Deficit; Organ; Outcome; Outcome Measure; Pathogenesis; Patient Care; Patient Recruitments; Patient Selection; Patients; Pharmaceutical Preparations; Physicians; Population; Postdoctoral Fellow; Prevalence; Pulmonary Fibrosis; Randomized Clinical Trials; Rare Diseases; Recurrence; Research; Research Personnel; Respiratory Failure; Sarcoidosis; Scientific Advances and Accomplishments; Scientist; Severities; Severity of illness; Students; Symptoms; Teacher Professional Development; Testing; Time; Training; Translational Research; Treatment/Psychosocial Effects; Underserved Population; United States; Universities; Validation; Woman; biomarker discovery; burden of illness; care delivery; chronic pain; clinical care; clinical investigation; clinical phenotype; cost effective; design; health care disparity; improved; individual patient; injured; lectures; medical specialties; meetings; multidisciplinary; novel marker; outcome forecast; precision medicine; programs; response; side effect; success; symposium; treatment strategy; treatment trial

Abstract Sarcoidosis is a multi-system disease of unknown cause characterized by noncaseating granulomatous inflammation that results in symptoms and organ dysfunction due to persistent inflammation and fibrosis. It predominately affects the lungs in over 90% of patients, but can injure any organ in the body, and disproportionately African Americans and women in prevalence and severity. At this time, there are no reliable, well-validated biomarkers for diagnosis, prognosis, response to therapy, or for specific vital organ involvement such as cardiac sarcoidosis. Therefore, to move the field forward, there is a critical need to discover and validate biomarkers for diagnosis, extent of organ involvement, and progression of disease. The annual conference for the Americas Association of Sarcoidosis and Other Granulomatous Disorders (AASOG) is the only meeting specifically devoted to the scientific understanding of the pathophysiology, as well as the diagnosis and clinical management of sarcoidosis. The meeting, entitled “Biomarkers for Severity, Disparity, and Therapy in Sarcoidosis: Discovery to Delivery” will be held at the University of Iowa April 12-13, 2019 and focus on development and testing of novel biomarkers for diagnosis prediction of disparate outcomes in underserved populations. The meeting program includes lectures and discussion by high level basic, translational, and clinical scientists. The meeting will also focus on faculty development of women and promote the training of junior faculty in the field. The specific aims of the conference are as follows: 1. To assemble high-level scientists and investigators in order to discuss current challenges and limitations to progress in the disease, and discuss methods that would lead to discovery of biomarkers that could predict or identify cause, pathogenesis, and response to therapy in any one individual patient. 2. Discuss how discovery and development of new biomarkers may enhance the delivery of care in disparate populations known to be afflicted with greater severity in sarcoidosis. 3. Provide a forum for collaboration and networking of investigators across the spectrum of basic science and clinical investigations, as well as different specialties, to develop future multi-center translational research. 4. To assemble a venue in which junior investigators, postdoctoral fellows, and students can present research, gain visibility, and attain mentorship in in the field of sarcoidosis. 5. Foster the development of women as scientists and academic faculty in the field of sarcoidosis.

摘要 结节病是一种病因不明的多系统疾病， 由于持续的炎症和纤维化导致症状和器官功能障碍的炎症。它 在超过90%的患者中主要影响肺部，但可以损伤身体的任何器官， 非裔美国人和妇女的患病率和严重程度不成比例。在这个时候，没有可靠的， 用于诊断、预后、治疗反应或特定重要器官受累的经过充分验证的生物标志物 例如心脏结节病。因此，为了推动这一领域的发展，迫切需要发现和 验证用于诊断、器官受累程度和疾病进展的生物标志物。年度 美洲结节病和其他肉芽肿性疾病协会（AASOG）的会议是 唯一专门致力于病理生理学的科学理解的会议，以及 结节病的诊断和临床治疗。这次会议题为“严重程度、差异、 和结节病治疗：发现交付”将于2019年4月12日至13日在爱荷华州大学举行， 专注于开发和测试新的生物标志物，用于诊断和预测不同的结果， 服务不足的人群。会议计划包括高水平的基础讲座和讨论， 翻译和临床科学家。会议还将重点讨论妇女教师的发展， 对该领域初级教员的培训。会议的具体目标如下： 1.召集高级别科学家和调查人员，讨论当前的挑战和局限性， 疾病的进展，并讨论方法，将导致发现的生物标志物，可以预测或 确定任何一个个体患者的病因、发病机制和对治疗的反应。 2.讨论新的生物标志物的发现和开发如何在不同的疾病中增强护理的提供。 已知患有更严重的结节病的人群。 3.为基础科学领域的研究人员提供一个合作和联网的论坛， 临床研究，以及不同的专业，以发展未来的多中心转化研究。 4.为初级研究人员、博士后研究员和学生提供一个展示研究成果的场所， 获得知名度，并获得结节病领域的指导。 5.促进发展妇女作为结节病领域的科学家和学术人员。